Skip to main content
OpenTrials
Completed

NCT Number: NCT01355198

Role of HIV on Glutathione Synthesis and Oxidative Stress

HIV infection is associated the development of increased oxidative stress and deficiency of glutathione (GSH), the dominant endogenous antioxidant protein, but the underlying mechanisms contributing to GSH deficiency are hitherto unknown. Furthermore GSH metabolism has not been studied in HIV patients, in whom the burden of risk factors promoting oxidative stress is highest. Our previous studies in non-HIV human subjects with diabetes-related oxidative stress and GSH deficiency have demonstrated that the latter is due to decreased synthesis of GSH. Importantly, short-term dietary supplementation with the simple GSH precursor amino-acids cysteine and glycine, boosted GSH synthesis and cellular concentrations, corrected GSH deficiency, and reduced oxidative stress and oxidant damage. The current proposal will study whether (1) defective synthesis underlies GSH deficiency in patients with HIV, and will test a simple, inexpensive and rational therapy based on protein supplementation to improve GSH synthesis and concentrations and lower markers of oxidative stress and oxidant damage in these patients; (2) study if correction of GSH deficiency is asssociated with any changes in (a) impaired mitochondrial fuel oxidation in the fasted and insulin stimulated states; (b) insulin sensitivity; (c) body composition and anthropometry; (d) forearm muscle strength; (e) plasma biochemistry, and (f) quality of life indices in these subjects.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(1) HIV infected patients with GSH deficiency

Exclusion criteria

  • renal impairment (serum Creatinine above 1.5mg/dL), liver impairment (ALT and AST > 2x upper limit of normal)
  • any hormonal disorders such as hypothyroidism, hypercortisolemia, hypogonadism, or diabetes mellitus on pharmacotherapy
  • evidence of infections other than HIV in the preceding 3 months
  • subjects with plasma triglyceride concentrations of ≥ 500mg/dL on triglyceride lowering therapy
  • BMI < 20
  • established heart disease
  • Co-existing viral hepatitis B and C

Treatment and study plan

Cysteine (as n-acetylcysteine) and glycine

Dietary Supplement

Cysteine and glycine will be supplemented at doses of 0.81 mmol/kg/d and 1.31 mmol/kg/d for 2 weeks each

Cysteine/glycine

Dietary Supplement

Subjects will receive oral dietary amino-acids (cystiene as n-acetylcysteine, and glycine)

Primary outcomes

  1. Glutathione synthesis rates and concentrations

    Time frame: 9 hours

    Fractional and absolute synthesis rates of glutathione and its concentrations

Secondary outcomes

  1. Mitochondrial fuel oxidation

    Time frame: Twice over 9 hours of the study on 2 occassions

    Lipolysis, fuel oxidation, and a hyperinsulinemic euglycemic clamp.

  2. Rates of fuel kinetics

    Time frame: 3 hours

    Measure rate of lipolysis (from infused 13C-palmitate) and recovery of 13CO2 (from infused acetate tracer)

  3. Insulin sensitivity

    Time frame: 3 hours

    Measure insulin sensitivity using a hyperglycemic euglycemic clamp

  4. Muscle strength

    Time frame: Done once in each 9-hour study

  5. Quality of life by SF36 questionnaire

    Time frame: Before and after

Sponsors and collaborators

Lead sponsor

Baylor College of Medicine

Other

Registry information

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
May 18, 2011
Registry last updated
Feb 7, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.